- Global Pharma News & Resources

Nicotine Addiction - Pipeline Review, H2 2018 Featuring Addex Therapeutics, Chronos Therapeutics, CV Sciences, Heptares Therapeutics, Indivior and Omeros -

The "Nicotine Addiction - Pipeline Review, H2 2018" drug pipelines has been added to's offering.

Nicotine Addiction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 16 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

  • Addex Therapeutics Ltd.
  • Chronos Therapeutics Ltd.
  • CV Sciences Inc.
  • Heptares Therapeutics Ltd.
  • Indivior plc
  • Omeros Corp.

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 19-Oct-2018